Half of US Adults Have Received at Least One COVID-19 Shot
WASHINGTON (AP) — Half of all adults in the U.S. have received at least one COVID-19 shot, the government announced Sunday, marking another milestone in the nation’s largest-ever vaccination campaign but leaving more work to do to convince skeptical Americans to roll up their sleeves.
Almost 130 million people 18 or older have received at least one dose of a vaccine, or 50.4% of the total adult population, the Centers for Disease Control and Prevention reported. Almost 84 million adults, or about 32.5% of the population, have been fully vaccinated.
The U.S. cleared the 50% mark just a day after the reported global death toll from the coronavirus topped a staggering 3 million, according to totals compiled by Johns Hopkins University, though the actual number is believed to be significantly higher.
The country’s vaccination rate, at 61.6 doses administered per 100 people, currently falls behind Israel, which leads among countries with at least 5 million people with a rate of 119.2. The U.S. also trails the United Arab Emirates, Chile and the United Kingdom, which is vaccinating at a rate of 62 doses per 100 people, according to Our World in Data, an online research site.
The vaccine campaign offered hope in places like Nashville, Tennessee, where the Music City Center bustled Sunday with vaccine seekers. High demand for appointment-only shots at the convention center has leveled off enough that walk-ins will be welcome starting this week.
Amanda Grimsley, who received her second shot, said she’s ready to see her 96-year-old grandmother, who lives in Alabama and has been nervous about getting the vaccine after having a bad reaction to a flu shot.
“It’s a little emotional. I haven’t been able to see my grandmother in a year and a half almost,” said Grimsley, 35. “And that’s the longest my entire family has ever gone without seeing her. And we’ll be seeing her in mid-May now.”
The states with the highest vaccination rates have a history of voting Democratic and supporting President Joe Biden in the 2020 election: New Hampshire at the top, with 71.1%, followed by New Mexico, Connecticut, Massachusetts and Maine, CDC data show.
The demand has not been the same in many areas of Tennessee — particularly, rural ones.
Tennessee sits in the bottom four states for rates of adults getting at least one shot, at 40.8%. It’s trailed only by Louisiana, Alabama and Mississippi — three other Southern states that lean Republican and voted for Donald Trump last fall.
Vaccination rates do not always align with how states vote. But polling from The Associated Press-NORC Center for Public Affairs Research has shown trends that link political leanings and attitudes about the vaccines and other issues related to the pandemic, which has killed more than 566,000 people in the U.S.
A poll conducted in late March found that 36% of Republicans said they will probably or definitely not get vaccinated, compared with 12% of Democrats. Similarly, a third of rural Americans said they were leaning against getting shots, while fewer than a fourth of people living in cities and suburbs shared that hesitancy.
Overall, willingness to get vaccinated has risen, polling shows.
In January, 67% of adult Americans were willing to get vaccinated or had already received at least one shot. The figure has climbed to 75%, according to the latest AP-NORC poll.
Nationwide, 24% of Black Americans and 22% of Hispanic Americans say they will probably or definitely not get vaccinated, down from 41% and 34% in January, respectively. Among white Americans, 26% now say they will not get vaccinated. In January, that number was 31%.
Dr. Anthony Fauci, the nation’s top infectious disease expert, said the goal is to get community figures, from athletes to clergy, to encourage vaccinations, particularly as the seven-day national average of cases remains over 60,000 new infections per day.
“What we are doing is we’re trying to get, by a community core, trusted messages that anyone would feel comfortable with listening to, whether you’re a Republican, a Democrat, an independent or whomever you are, that you’re comfortable,” Fauci said Sunday on ABC’s “This Week.”
Fauci also indicated Sunday that the government will likely move to resume use of Johnson & Johnson’s COVID-19 vaccine this week, possibly with restrictions or broader warnings after reports of some very rare blood clot cases.
In a series of news show interviews, Fauci said he expects a decision when advisers to the CDC meet Friday to discuss the pause in J&J’s single-dose vaccine.
“I would be very surprised if we don’t have a resumption in some form by Friday,” he said. “I don’t really anticipate that they’re going to want it stretch it out a bit longer.”
Fauci, who is President Joe Biden’s chief medical adviser, said he believed federal regulators could bring the shots back with limits based on age or gender, or with a blanket warning, so the vaccine is administered in a way “a little bit different than we were before the pause.”
The J&J vaccine was thrown into limbo after the CDC and the Food and Drug Administration said last week that they needed more evidence to decide if a handful of unusual blood clots were linked to the shot — and if so, how big the risk is.
The reports are rare — six cases out of more than 7 million U.S. inoculations with the J&J vaccine. The clots were found in women between the ages of 18 and 48. One person died.
Authorities stressed that they have found no sign of clot problems with the most widely used COVID-19 vaccines in the U.S. — from Moderna and Pfizer.
Mattise reported from Nashville, Tennessee.
In The News
The U.S. Environmental Protection Agency and World Health Organization recently signed a five-year Memorandum of Understanding with new actions for protecting human health... Read More
The U.S. Environmental Protection Agency and World Health Organization recently signed a five-year Memorandum of Understanding with new actions for protecting human health and the environment. “The COVID-19 pandemic has highlighted the intimate links between humans and our environment,” said Dr. Tedros Adhanom Ghebreyesus, WHO director-general, in a written statement. ... Read More
A recent study published in JAMA Internal Medicine shows that Black nursing home residents with advanced dementia likely receive more aggressive care... Read More
A recent study published in JAMA Internal Medicine shows that Black nursing home residents with advanced dementia likely receive more aggressive care than non-Black residents. A team of researchers from Massachusetts, Tennessee, Georgia and North Carolina conducted the qualitative study with 169 staff interviews in 14 nursing homes... Read More
The University of California San Diego Health now offers a new treatment for patients with treatment-resistant depression, called transcranial magnetic stimulation.... Read More
The University of California San Diego Health now offers a new treatment for patients with treatment-resistant depression, called transcranial magnetic stimulation. TMS is a treatment approved by the U.S. Food and Drug Administration to stimulate nerve cells in areas of the brain associated with major depression. The... Read More
In Rhode Island, Gov. Dan McKee recently signed an executive order to halt the enforcement of the Nursing Home Staffing and Quality Care... Read More
In Rhode Island, Gov. Dan McKee recently signed an executive order to halt the enforcement of the Nursing Home Staffing and Quality Care Act, which he signed into law last May to give nursing homes across the state a higher staff-to-patient ratio. The Nursing Home Staffing and Quality Care... Read More
Researchers from the Yale School of Public Health recently developed a small, lightweight, inexpensive wearable device — the Fresh Air Clip —... Read More
Researchers from the Yale School of Public Health recently developed a small, lightweight, inexpensive wearable device — the Fresh Air Clip — that is capable of detecting possible exposure to SARS-CoV-2. The clip was developed to help individuals in high-risk settings to detect low levels of virus and... Read More
On Tuesday, Pfizer-BioNTech announced they will begin a clinical trial to develop an omicron-specific COVID-19 vaccine candidate. “Emerging data indicate vaccine-induced protection... Read More
On Tuesday, Pfizer-BioNTech announced they will begin a clinical trial to develop an omicron-specific COVID-19 vaccine candidate. “Emerging data indicate vaccine-induced protection against infection and mild to moderate disease wanes more rapidly than was observed with prior strains,” said Prof. Ugur Sahin, CEO and co-founder of BioNTech, in... Read More